hackint0sh/New-Dataset huggingface dataset:
Goal is to identify main barriers for conventional rehabilitation as well as to assess willingness to participate in cardiac telerehabilitation, main barriers and willingness-to-pay for cardiac telerehabilitation. conditions: Cardiac Rehabilitation studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 60 type: ACTUAL name: Questionnaire measure: Willingness to participate in telerehabilitation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Jessa Hospital city: Hasselt state: Limburg zip: 3500 country: Belgium lat: 50.93106 lon: 5.33781 hasResults: False
nctId: NCT06306222 id: GR-2021-12375430 briefTitle: Thulium Fiber Laser vs. Holmium:YAG Laser for the Ureteroscopic Treatment of Patients With Urinary Stone Disease overallStatus: RECRUITING date: 2023-11-23 date: 2025-11-23 date: 2026-02-23 date: 2024-03-12 date: 2024-03-12 name: IRCCS San Raffaele class: OTHER briefSummary: This is a randomized controlled trial which aims to compare the efficacy and safety of Thulium fiber laser (TFL) and holmium:yttrium-aluminum-garnet (Ho:YAG) laser ablation during the treatment of upper urinary tract stone disease with flexible ureteroscopy, demonstrating clinical superiority of TFL. conditions: Kidney Stone conditions: Ureteral Stone studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 120 type: ESTIMATED name: Laser lithotripsy measure: Lithotripsy speed measure: Stone free rate sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milan country: Italy name: Alessia D'Arma role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06306209 id: DeFLAME briefTitle: Inflammatory Control of Antidepressant Efficacy: a Pharmaco-epigenetic Approach overallStatus: RECRUITING date: 2021-05-18 date: 2024-11-30 date: 2025-01-14 date: 2024-03-12 date: 2024-03-12 name: IRCCS San Raffaele class: OTHER briefSummary: Major depressive disorder (MDD) is a chronic, recurring and potentially life-threatening illness that affects up to 10% of the population across the globe.It posits that the increase in serotonin levels induced by Selective Serotonin Reuptake Inhibitors (SSRIs) does not affect mood per se, but enhances brain plasticity and thus amplifies the influence of the environment on the individual. Thus, SSRI treatment has not a univocal effect but, in a favorable environment, it would lead to a reduction of symptoms while in a stressful environment might lead to a worse prognosis.Such innovative view opens new perspectives on how to improve SSRI efficacy by controlling the environment. However, often it is not possible to act on the quality of the living environment because of constraints due to patient's personal history and unchangeable life circumstances. In these cases, the pharmacological modulation of the factors underlying the link between living environment and SSRI efficacy represents a novel and desirable strategy to improve treatment outcome even in patients living in adverse conditions, which are very common in depressed patients. Inflammatory levels are markedly affected by the socioeconomic status and thus by the quality of the living environment. The hypothesis of the present project is that inflammation mediates the influence of the environment on SSRI outcome.Therefore, the control of inflammatory levels is a promising strategy to improve treatment efficacy and overcome the limited SSRI efficacy, especially when administered in patients living in adverse conditions. A further hypothesis is that the influence of the environment on inflammation, in turn affecting SSRI efficacy, occurs through epigenetic modifications. Therefore, the project aims at developing a pharmaco-epigenetic approach as effective treatment for MDD. In addition, through neuroimaging investigations, it will provide important information about functional and structural brain modifications associated to SSRI efficacy in patients.
Both males and females will be considered because MDD is twice as common in women than men, suggesting that different mechanisms may underlie the psychopathology in the two sexes. conditions: Mood Disorders conditions: Major Depressive Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management measure: The potential role of inflammation as the causal link between the quality of the environment and SSRI efficacy measure: interaction between early stress and recent stress on the response to treatment and the role of inflammation measure: identification of neurobiological predictors of response to treatment measure: identification of neurobiological predictors of response to treatment measure: identification of neurobiological predictors of response to treatment measure: epigenetic changes in cytokine regulating genes which could mediate the effect of stress on response to treatment. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milan state: Mi zip: 20132 country: Italy name: Sara sp Poletti, phd role: CONTACT phone: +390226433156 email: poletti.sara@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06306196 id: IVI Hecolin S001 briefTitle: Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-01 date: 2026-01 date: 2024-03-12 date: 2024-03-12 name: International Vaccine Institute class: OTHER name: Xiamen Innovax Biotech Co., Ltd name: Bill and Melinda Gates Foundation briefSummary: The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses (0, 1 and 6 months) and to assess and descriptively compare safety profile data intra and inter age Strata. As secondary objectives, Geometric Mean Concentration (GMC) of anti-HEV IgG ELISA will be evaluated 4 weeks after 3 doses (0, 1 and 6 months) and 4 weeks after 2 doses (0- and 6-months dose) in healthy children. SR and GMC will also be evaluated 24 weeks after 3 doses and 2 doses. The immune response will be compared among adult participants between HIV positive and HIV negative individuals and between virally suppressed and virally unsuppressed HIV positive individuals conditions: Hepatitis E Virus Infection studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Single whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 860 type: ESTIMATED name: Hecolin® Recombinant Hepatitis E Vaccine name: Isotonic Sodium Chloride injection measure: Seroresponse rate measure: Proportion of immediate adverse events measure: Proportion of solicited local and systemic adverse events measure: Proportion of unsolicited adverse events measure: Proportion of SAEs, MAAEs and AESIs measure: GMC of anti-HEV IgG measure: SR measure: GMC of anti-HEV IgG measure: SR and GMC of anti-HEV IgG measure: SR measure: GMC of anti-HEV IgG measure: SR measure: GMC of anti-HEV IgG measure: SR measure: GMC of anti-HEV IgG measure: SR measure: GMC of anti-HEV IgG measure: SR and GMC of anti-HEV IgG measure: SR and GMC of anti-HEV IgG measure: Safety in all participants as per gender distribution and serostatus sex: ALL minimumAge: 2 Years maximumAge: 45 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06306183 id: 2024-2829 briefTitle: Effect of Vitamin C on Pain Reduction After an Emergency Department Visit acronym: Vicamed overallStatus: NOT_YET_RECRUITING date: 2024-11 date: 2026-11 date: 2028-03 date: 2024-03-12 date: 2024-03-12 name: Hopital du Sacre-Coeur de Montreal class: OTHER name: Hopital de l'Enfant-Jesus name: The Ottawa Hospital briefSummary: Emergency department (ED) clinicians often prescribe anti-inflammatory drugs (NSAIDs) to manage acute musculoskeletal (MSK) pain (e.g.: fracture, sprain, back pain). However, even short-term NSAIDs use can have significant gastrointestinal, cardiovascular, MSK and renal adverse effects. For this reason, some patients cannot take or tolerate NSAIDs. Recent evidence has shown that vitamin C has some analgesic and anti-inflammatory properties particularly in postoperative context and prevent specific types of chronic pain. Furthermore, vitamin C is safe and associated with very few adverse events. The primary objective of this study is to determine whether vitamin C can reduce pain intensity during a seven-day period following an ED visit for acute MSK pain.
The investigators propose to compare two groups of patients, one receiving 900 mg of vitamin C to another receiving a placebo, twice a day for seven days. Both groups will consume acetaminophen slow release 650 mg two pills every eight hours regularly. Naproxen 500 mg (NSAID) will be used as a rescue medication if the patient's pain is not relieved. Participants will be ≥18 years of age, treated in ED for acute MSK pain present for less than 48 hours with pain intensity at triage of ≥ 4 on a 0-10 numeric rating scale, and discharged by an ED clinician with an NSAIDs prescription without opioids. The level of pain intensity during a seven-day period will be assessed daily using an electronic or paper diary, as well as pain relief, pain medication consumption, and adverse events. Three months after the injury, participants will also be contacted to assess the presence of chronic pain. The investigators hypothesized that vitamin C will reduce pain intensity and chronic pain development at three months.
This research could provide a safe alternative to patients who are unable to take NSAIDs. It may also contribute to the reduction of the burden associated with chronic pain development. conditions: Pain, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-blind randomized placebo-controlled trial primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 546 type: ESTIMATED name: Acetaminophen and Vitamin C with Naproxen rescue name: Acetaminophen and Placebo with Naproxen rescue measure: Daily pain intensity measure: NSAIDs consumption measure: Pain relief measure: New analgesic prescriptions measure: Adverse events measure: Quality of life improvement at seven days measure: Quantity of Healthcare visits measure: Prevalence of chronic pain measure: Prevalence of complex regional pain syndromes for limb fractures measure: Quality of life improvement at 90 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hopital du Sacre-Coeur de Montreal city: Montreal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06306170 id: GYN-ART briefTitle: Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART) acronym: GYN-ART overallStatus: RECRUITING date: 2024-02-15 date: 2027-02-15 date: 2029-02-15 date: 2024-03-12 date: 2024-03-12 name: IRCCS San Raffaele class: OTHER briefSummary: This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed. conditions: Gynecologic Cancer conditions: Radiotherapy Side Effect conditions: Radiotherapy; Complications conditions: Survivorship conditions: Progression, Disease conditions: Progression, Clinical studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: Image Guided Radiotherapy measure: Local Relapse Free Survival measure: Regional Relapse Free Survival measure: Distant Metastases Free Survival measure: Disease Free Survival measure: Overall Survival measure: Cancer Specific Survival measure: Acute toxicity measure: Late toxicity measure: Predictive factors for disease progression and death measure: Radiomic predictive factors for disease progression and death sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: San Raffaele Scientific Institute status: RECRUITING city: Milan state: MI zip: 20132 country: Italy name: Andrei Fodor, M.D. role: CONTACT phone: +390226437634 email: fodor.andrei@hsr.it name: Nadia G Di Muzio, Prof role: CONTACT phone: +390226437643 email: dimuzio.nadia@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06306144 id: 69HCL23_0691 briefTitle: Early-phase Telecare Programs for Minor Stroke acronym: COGaDOM overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-07-01 date: 2027-07-01 date: 2024-03-12 date: 2024-04-18 name: Hospices Civils de Lyon class: OTHER briefSummary: Minor strokes (few acute neurological symptoms ; NIHSS score \<5), represent almost 65% of cerebrovascular ischemic events. The increasing incidence of stroke in people under 65, together with advances in diagnostic and revascularization techniques, mean that post-stroke life expectancy is now in the order of decades. Most patients with minor stroke are rapidly discharged from hospital, with follow-up focused on secondary prevention and they are offered little or no rehabilitation.
However, up to 70% of patients with minor stroke experience difficulties resuming their social or professional activities, which can lead to social and economic disruption (delayed/compromised return to work) and an increased risk of depression. While some care recommendations exist for this population, in France there is no consensus nor identified care pathway for follow-up assessment or management of these patients. Furthermore, existing services are unevenly distributed across the country, and research into the effectiveness of rehabilitation is still scarce, leading to uncertainty as to which interventions should be prioritized to decrease difficulties related to cognitive impairment.
nctId: NCT06306131 id: IG-23-002 id: 1R43HD107861-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R43HD107861-01A1 briefTitle: Phase II Study of Ovulation in Obese Women overallStatus: RECRUITING date: 2023-12-10 date: 2024-12-01 date: 2025-01-31 date: 2024-03-12 date: 2024-03-12 name: InnovaGyn, Inc. class: OTHER name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) briefSummary: The goal of this clinical trial is to compare the delay in ovulation between placebo to levonorgestrel plus meloxicam in obese women with normal menses. The main questions it aims to answer are:
Researchers will compare the placebo cycle to levonorgestrel plus meloxicam to see if ovulation is delayed, there is unscheduled vaginal bleeding, menstrual onset is delayed or there is an abnormal amount or duration of menses, there is any difference in treatment emergent side effects and any change in vital signs conditions: Pregnancy Prevention studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Placebo controlled in first cycle with levonorgestrel plus meloxicam in second menstrual cycle. primaryPurpose: OTHER masking: SINGLE maskingDescription: The intervention will be masked to the laboratory preforming the analysis of the urinary metabolites. The statistician, clinicians, coordinators and participants will be aware of the medication being studied. whoMasked: OUTCOMES_ASSESSOR count: 22 type: ESTIMATED name: Levonorgestrel 0.15 milligram name: Meloxicam 15 milligram name: calcium carbonate 750 milligram measure: Interval from first dose to evidence of ovulation. measure: Change in blood pressure measure: Change in Pulse measure: Unscheduled endometrial bleeding and changes in interval, amount and duration of menstrual bleeding. sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Carolina Women's Research and Wellness Center status: RECRUITING city: Raleigh state: North Carolina zip: 27713 country: United States name: Andrea S. Lukes, MD role: CONTACT phone: 919-251-9223 email: andrealukes@cwrwc.com name: Janet F. Davis role: CONTACT phone: 9192519223 email: janet@cwrwc.com name: Andrea S. Lukes, MD role: PRINCIPAL_INVESTIGATOR lat: 35.7721 lon: -78.63861 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-04-17 uploadDate: 2023-10-16T10:12 filename: ICF_000.pdf size: 336680 hasResults: False
nctId: NCT06306118 id: 35-046 ex 22/23 briefTitle: Autoguide Positioning Device for Multiple Stereotactic Biopsies acronym: AMB overallStatus: RECRUITING date: 2024-04-15 date: 2025-02 date: 2025-10 date: 2024-03-12 date: 2024-03-12 name: Medical University of Graz class: OTHER briefSummary: The purpose of this clinical study should be that, in the context of planned resections of glial brain tumors, pieces of tissue (biopsies) are removed from the tumor at several specific locations before the actual tumor resection takes place.
To carry out these biopsies, a robot positioning device (AutoGuide®) will be used that has already been approved and tested for this type of intervention. The use of the AutoGuide® is intended to ensure that the tumor sample is taken with the greatest possible precision. conditions: Multiple Stereotactic Tumor Biopsies During a Brain Tumor Resection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection measure: Biopsy Results sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Graz status: RECRUITING city: Graz state: Styria zip: 8036 country: Austria name: Stefan Wolfsberger, Prof. role: CONTACT phone: +43031638583102 email: stefan.wolfsberger@medunigraz.at lat: 47.06667 lon: 15.45 hasResults: False
nctId: NCT06306105 id: 23-118-B briefTitle: Assessment of Anti-aging Efficacy of Marine Collagen Peptides overallStatus: RECRUITING date: 2024-03-04 date: 2024-10-31 date: 2024-12-01 date: 2024-03-12 date: 2024-03-19 name: TCI Co., Ltd. class: INDUSTRY briefSummary: To assess the anti-aging efficacy of Marine Collagen Peptides on skin, hair and finger nails for human conditions: Skin Condition conditions: Hair Fragility conditions: Nails, Ingrown studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Marine Collagen Peptides name: placebo drink measure: The change of skin hydation measure: The change of skin wrinkles measure: The change of skin elasticity measure: The change of skin collagen density measure: The change of hair diameters measure: The change of hair loss amount measure: The change of hair roots diameters measure: The change of hair density measure: The change of hair follicle strength measure: The change of thumbs nail color measure: The change of nails appearence measure: The change of nails growth measure: The degree of nails fragility measure: The change of self-assessment skin, hair, and nails condition sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chia Nan University of Pharmacy & Science status: RECRUITING city: Pingtung zip: 928 country: Taiwan name: Chia-Hua Liang role: CONTACT phone: +886-06-2664911 phoneExt: 2441 email: tinna_ling@mail.cnu.edu.tw name: Ping Lin role: CONTACT phone: +886-02-879778111 email: candice.lin@tci-bio.com lat: 22.67135 lon: 120.48814 hasResults: False
nctId: NCT06306092 id: 2023-02885-01 briefTitle: Promoting Teenage Sleep for Improved Mental Health and School Performance acronym: TeenSleep overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2028-06 date: 2030-06 date: 2024-03-12 date: 2024-03-12 name: Kristianstad University class: OTHER name: Karolinska Institutet name: Örebro University, Sweden name: Academic Primary Health Care Centre, Region Stockholm briefSummary: The overall aim of this project is to evaluate the effectiveness of two school-based programs that have the potential to promote adolescent sleep and prevent future depressive symptoms. The programs will be offered to students aged 13-19 at Swedish high schools and upper secondary schools at the classroom level. The students will be compared to teaching as usual (control group). conditions: Mental Health Issue conditions: Insomnia conditions: Depression conditions: Anxiety conditions: Daytime Sleepiness conditions: Wellness, Psychological studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 3000 type: ESTIMATED name: Sleep on Schedule name: Technology restriction measure: Change in sleep duration, hours and minutes measure: Change in Hospital Anxiety and Depression Scale scores measure: Change in Adolescent Sleep Hygiene Scale scores measure: Change in Insomnia Severity Index score measure: Change in EuroQol Visual Analog Scale (EQ VAS) score measure: Change in CHU9D Child Health Utility 9D (CHU9D) scores measure: Change in Sleep knowledge measure: Change in electronic media use measure: Change in sleep habits measure: Change in meta-cognitions measure: Change in motivation sex: ALL minimumAge: 13 Years maximumAge: 19 Years stdAges: CHILD stdAges: ADULT typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-02-23 uploadDate: 2024-03-07T03:17 filename: Prot_SAP_000.pdf size: 264890 hasResults: False
nctId: NCT06306079 id: KKUMC id: Abdullah Al Assiri type: OTHER domain: King Khalid University Medical City id: Prof Pip Logan type: OTHER domain: Professor of Rehabilitation Research, University of Nottingham, UK. id: Professor Ana Valdes type: OTHER domain: Professor of Molecular & Genetic Epidemiology, University of Nottingham, UK. id: Dr. Benjamin Smith type: OTHER domain: Doctor of Physiotherapy, Division of Rehabilitation and Ageing, University of Nottingham. UK. briefTitle: Using Gait Modification to Treat Knee Osteoarthritis in Saudi Arabia: Possibilities and Acceptability. overallStatus: COMPLETED date: 2022-04-13 date: 2022-10-15 date: 2022-12-30 date: 2024-03-12 date: 2024-03-12 name: King Khalid University class: OTHER name: University of Nottingham briefSummary: A variety of biomechanical gait modification interventions can elevate knee loading and improve knee symptoms in knee osteoarthritis patients. However, there was a lack of acceptability and adherence regarding modification interventions without any explanation.
3. A small group of knee osteoarthritis patients and their physiotherapists who participated in phase (2) will be asked to participate in a descriptive survey in phase (3). To examine the acceptability and feasibility of the study intervention in phase (2). conditions: Osteoarthritis, Knee conditions: Pain conditions: Biomechanical Lesion studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A gait modification (Lateral wedge insole) program will be conducted over 4 to 6 weeks in the physiotherapy gym or adjusted treadmill and outside the clinic during the day (at least 8 hours per day).